Dexcom G7 is available for people with all types of diabetes ages two years and older, giving more Canadians than ever access to a simple, accurate1 and effective diabetes management solutionBURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDA
Partnership between two Canadian life sciences leaders offers a commercial GMP manufacturing solution for Acuitas’ licensed partners developing promising next generation therapiesCHARLOTTETOWN, Prince Edward Island & VANCOUVER, British Columbia--(BUSIN
CHAPEL HILL, N.C. & TORONTO & LONDON & ZUG, Switzerland--(BUSINESS WIRE)--#HEOR--AESARA, INC. is pleased to announce its recent certifications by the Women’s Business Enterprise National Council (WBENC) and National Minority Supplier Development Council
Gains Nasal Delivery Technologies and Expands Product PipelineTAMPA, Fla. & LAS VEGAS--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Odyssey Health, Inc. (OTCQB: ODYY) (“Odyssey”) announce the signi
More than 200 e-Emphasys ERP clients gathered in Nashville for three days of hands-on learning, networking and collaboration; sights now set on IntelliDealer user conference in February 2024CARY, N.C.--(BUSINESS WIRE)--e-Emphasys Technologies Inc., a glo
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment
MISSISSAUGA, Canada--(BUSINESS WIRE)--Eurofins CDMO Alphora Inc. is pleased to announce the launch of its Biologics initiative, as part of its vision to diversify and grow within the contract development and manufacturing industry in North America. The mu
The Psybrary™ portfolio includes numerous unique, previously unreported molecules, which are protected by Enveric’s expansive and growing intellectual property estateCAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric”
- Topline efficacy data expected in Q4 2023 - - Preparations are underway to scale the CYB003 program to a potential Phase 3 study in early 2024 -TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a c
Conference call and live webcast on Friday, October 13, 2023 at 5:30 p.m. ETCAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, to
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.